Prevención de la infección por virus de papiloma humano mediante vacunación

Abstract

The prophylactic vaccine against human papillomavirus is a promising advance in health for the prevention of cancers related to this virus, have shown after a decade a substantial reduction in the incidence and prevalence of cervical cancer and vulva with protection of his flocks. Although multiple studies have demonstrated the efficacy and safety of this vaccine, several questions arise about effectiveness, safety, number of doses and gender equity that have put vaccination programs at risk, follow-up studies of immunized people are lacking To determine how long they are protected, however, with the reduction of cases of cancers due to vaccines, cancer prevention screening cannot be left aside, since vaccines currently commercialized do not cover all types of papillomavirus and in developing countries still do not have the nonvalent vaccine that covers 5 more genotypes of the virus. Objective: To support the prevention of Human Papilloma Virus with prophylactic vaccines. Method: This is a systematic review study of a descriptive type, a database search was carried out: ScienceDirect, Springer, Wiley Online Library of scientific articles in the last 5 years. This search included systematic studies, randomized clinical trials, descriptive studies.